ARTBIO

aid: artbio
name: ARTBIO
description: ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of targeted Alpha Radioligand Therapies
  (ARTs) built on the lead-212 (212Pb) isotope. Founded in 2021 out of research at the University of Oslo and Norway's Radium
  Hospital by Roy Larsen and Oyvind Bruland - the scientific co-founders behind Xofigo - the company pairs a differentiated
  oncology pipeline with its proprietary AlphaDirect isotope-production technology, a first-of-its-kind 212Pb isolation method
  intended to enable distributed manufacturing and reliable supply of alpha radioligand therapies. Its lead program AB001
  (212Pb-NG001) is in first-in-human Phase 1 trials in metastatic castration-resistant prostate cancer, with additional preclinical
  and discovery programs across breast, head and neck, lung, pancreatic and other solid tumors. ARTBIO operates from Cambridge,
  Massachusetts and Oslo, is backed by F-Prime Capital, Third Rock Ventures, Omega Funds, Sofinnova Partners, B Capital, ARE
  and QIA, and is privately held. It publishes no public API, developer portal, SDK or machine-readable specification - software
  is not its product.
url: https://raw.githubusercontent.com/api-evangelist/artbio/refs/heads/main/apis.yml
image: https://artbio.com/icons/icon-512x512.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Radiopharmaceuticals
- Oncology
- Clinical Trials
- Life Sciences
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/artbio-domain-security.yml
- type: Website
  url: https://artbio.com/
- type: PrivacyPolicy
  url: https://artbio.com/privacy-policy
- type: TermsOfService
  url: https://artbio.com/terms-of-service
- type: News
  url: https://artbio.com/#news
- type: Careers
  url: https://artbio.com/#careers
- type: Contact
  url: mailto:info@artbio.com
- type: LinkedIn
  url: https://www.linkedin.com/company/artbio-inc/
- type: Twitter
  url: https://twitter.com/artbio_inc
- type: Technology
  url: https://artbio.com/our-approach
- type: ClinicalTrials
  url: https://artbio.com/clinical-trials
- type: LLMsTxt
  url: llms/artbio-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: ARTBIO is a clinical-stage radiopharmaceutical company whose product is a 212Pb alpha radioligand therapy and an
    isotope-manufacturing process, not software — artbio.com is a five-page corporate site (pipeline, approach, clinical trials,
    news, careers) that returns 404 for every spec, docs and .well-known path probed, and no api./docs./ developer./portal./app.
    subdomain resolves in DNS at all.
  evidence:
  - url: https://artbio.com/openapi.json
    status: 404
  - url: https://artbio.com/api-docs
    status: 404
  - url: https://artbio.com/docs
    status: 404
  - url: https://artbio.com/graphql
    status: 404
  - url: https://artbio.com/llms.txt
    status: 404
  - url: https://artbio.com/.well-known/agent-card.json
    status: 404
  - url: https://artbio.com/.well-known/agent.json
    status: 404
  - url: https://artbio.com/.well-known/security.txt
    status: 404
  - url: https://api.artbio.com/openapi.json
    status: 0
  - url: https://docs.artbio.com/
    status: 0
  checked: '2026-08-06'